JP2007295833A - Life style disease-preventive food containing frozen dry powder of dioscorea batatas - Google Patents

Life style disease-preventive food containing frozen dry powder of dioscorea batatas Download PDF

Info

Publication number
JP2007295833A
JP2007295833A JP2006125678A JP2006125678A JP2007295833A JP 2007295833 A JP2007295833 A JP 2007295833A JP 2006125678 A JP2006125678 A JP 2006125678A JP 2006125678 A JP2006125678 A JP 2006125678A JP 2007295833 A JP2007295833 A JP 2007295833A
Authority
JP
Japan
Prior art keywords
life style
food
powder
group
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006125678A
Other languages
Japanese (ja)
Inventor
Masao Onishi
正男 大西
Kazunori Hironaka
和憲 弘中
Michihiro Fukushima
道広 福島
Naomichi Nishimura
直道 西村
Kiyoshi Oba
潔 大庭
Mika Kawahara
美香 川原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokachiken Shiko Kiko
Original Assignee
Tokachiken Shiko Kiko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokachiken Shiko Kiko filed Critical Tokachiken Shiko Kiko
Priority to JP2006125678A priority Critical patent/JP2007295833A/en
Publication of JP2007295833A publication Critical patent/JP2007295833A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide frozen dry powder of Dioscorea batatas comprising food raw material having a function preventing or ameliorating life style disease caused by inadequate dietary habit or lack of exercise. <P>SOLUTION: The life style disease-preventive or -ameliorating food contains uncooked Dioscorea batatas powder. Earnest effort to solve the life style disease results in finding that the uncooked Dioscorea batatas powder has the function preventing or ameliorating the life style disease so as to accomplish the invention. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

本発明は、非加熱長いも粉末の機能性食品としての利用に関する。   The present invention relates to the use of non-heated long powder as a functional food.

生活習慣病には、さまざまな病気や症状があり、どんな病気が発症するか、また発症後にどのような速さで進行するかは、個人の体質や生活習慣によって異なる。生活習慣病の恐ろしい点は、その多くが長い期間にわたって自覚症状がほとんどなく、知らず知らずのうちに症状が進行していくことであり、たとえば、「高脂血症」「高血圧」「糖尿病」を挙げることができる。これらの病気は、そのまま放置しておくと、たとえば「動脈硬化」という血管の不調を引き起こし、やがて心臓病や脳卒中などの生命に関わる重大な病気につながる危険性が高まる。また、この3つの病気は単独で発症することもあるが、それぞれが原因とも結果ともなることで合併症を誘発することもあり、そうなると治療は困難の度合いを増し、いわゆる「生活の質(QOL)」を極端に引き下げることになる。   There are various illnesses and symptoms in lifestyle-related diseases, and what kind of illness develops and how fast it progresses after onset varies depending on individual constitution and lifestyle. The terrible point of lifestyle-related diseases is that many of them have almost no subjective symptoms over a long period of time, and the symptoms progress unknowingly. For example, “hyperlipidemia” “hypertension” “diabetes” Can be mentioned. If these diseases are left as they are, for example, a blood vessel malfunction such as “arteriosclerosis” is caused, and the risk of eventually leading to serious life-related diseases such as heart disease and stroke increases. In addition, these three diseases may occur alone, but each may cause and result in complications, and the treatment increases the degree of difficulty, so-called “quality of life (QOL)”. ) ”Will be drastically reduced.

したがって、高血糖、高インスリン血症、高脂血症等の生活習慣病発症のリスクファクターを改善するような生理機能性を有する食品成分の開発が広く待ち望まれている。   Accordingly, the development of food components having physiological functions that improve risk factors for the development of lifestyle-related diseases such as hyperglycemia, hyperinsulinemia, and hyperlipidemia is awaited widely.

非加熱長いも粉末の生理機能は知られていなかった。   The physiological function of the powder was not known even though it was not heated.

不適切な食生活又は運動不足に起因する生活習慣病を予防又は改善する作用を有する食品素材を提供する。   Provided is a food material having an action to prevent or ameliorate lifestyle-related diseases caused by inappropriate eating habits or lack of exercise.

本発明者は、上記課題を解決するために鋭意努力した結果、非加熱長いも粉末が、生活習慣病を予防又は改善する作用を有することを見出し、本発明を完成させた。
すなわち、本発明は、非加熱長いも粉末を含む、生活習慣病の予防食品又は生活習慣病の改善食品に関する。
As a result of diligent efforts to solve the above-mentioned problems, the present inventors have found that non-heated and long powder has an action of preventing or improving lifestyle-related diseases, and completed the present invention.
That is, the present invention relates to a food for preventing lifestyle-related diseases or a food for improving lifestyle-related diseases, which includes a non-heated long powder.

すなわち、本発明の非加熱長いも粉末は、加熱していない長いもを凍結乾燥することによって得ることができる。本発明の非加熱長いも粉末の組成は、たとえば、100g当たり、水分1.2g、タンパク質10.1g、脂質0.6g、炭水化物83.4g(総食物繊維5.1g、水溶性食物繊維1.9g、不溶性食物繊維3.2g)、灰分4.7g、エネルギー379kcalである。   That is, the non-heated long powder of the present invention can be obtained by lyophilizing a long unheated powder. The composition of the non-heated long powder of the present invention is, for example, 1.2 g water, 10.1 g protein, 0.6 g fat, 83.4 g carbohydrate (5.1 g total dietary fiber, 1.9 g water-soluble dietary fiber per 100 g). Insoluble dietary fiber 3.2 g), ash content 4.7 g, energy 379 kcal.

本発明の非加熱長いも粉末の製造原料である長いもとしては、従来公知の長いもであればどのようなものでも使用することができる。   Any non-heated long powder as a raw material for producing powder of the present invention can be used as long as it is conventionally known.

本発明の機能性食品は、上記本発明に係る非加熱長いも粉末を含むものであればよい。したがって、当該非加熱長いも粉末のみからなる食品でもよく、当該非加熱長いも粉末以外の成分を含む食品でもよい。本発明の非加熱長いも粉末以外の成分としては、脂質代謝調節作用を阻害しないものであれば特に限定されるものではない。具体的には、例えば、植物および動物性タンパク質、炭水化物、食物線維、脂質、各種ビタミン、ミネラル類等を挙げることができる。食品の形状についても特に限定されるものではなく、固体状、液体状、粉末状、ペースト状等様々な形状とすることができる。   The functional food of the present invention only needs to contain the non-heated long powder according to the present invention. Therefore, the food which consists only of the said non-heated long powder may be sufficient, and the food which contains components other than the said non-heated long powder may be sufficient. The components other than the non-heated long powder of the present invention are not particularly limited as long as they do not inhibit the lipid metabolism regulating action. Specific examples include plant and animal proteins, carbohydrates, dietary fiber, lipids, various vitamins, minerals, and the like. The shape of the food is not particularly limited, and may be various shapes such as a solid, liquid, powder, and paste.

本発明の機能性食品素材は、上記非加熱長いも粉末を含むものであるため、脂質代謝改善効果を有している食品である。したがって、当該食品は、不適切な食生活または運動不足に起因する生活習慣病を予防および改善する作用を有する。上記不適切な食生活または運動不足に起因する生活習慣病としては、肥満、高脂血症、高血圧症、糖尿病を挙げることができ、本発明の食品は肥満、高脂血症、高血圧症または糖尿病の少なくともいずれかを予防および改善する作用を有する。また、この生活習慣病予防改善効果は、具体的には
血中HDLコレステロール濃度の上昇、血中LDLコレステロール濃度の減少、血中中性脂肪濃度の低下の少なくともいずれかの作用、すなわち脂質代謝調節作用により得られる効果である。
The functional food material of the present invention is a food having an effect of improving lipid metabolism because it contains the above non-heated long powder. Therefore, the food has an action of preventing and ameliorating lifestyle-related diseases caused by inappropriate eating habits or lack of exercise. Examples of lifestyle-related diseases resulting from the inappropriate diet or lack of exercise include obesity, hyperlipidemia, hypertension, and diabetes, and the food of the present invention is obesity, hyperlipidemia, hypertension or It has an action to prevent and ameliorate at least one of diabetes. Further, this lifestyle-related disease prevention / improvement effect is specifically the action of at least one of an increase in blood HDL cholesterol concentration, a decrease in blood LDL cholesterol concentration, and a decrease in blood triglyceride concentration, ie, lipid metabolism regulation. This is an effect obtained by the action.

本発明に係る食品の具体例としては、例えば、いわゆる栄養補助食品(サプリメント)として本発明に係る食品素材を含む錠剤、顆粒剤、散剤、ドリンク剤等を挙げることができる。これ以外に、当該食品素材を含む調味料、菓子、パン、惣菜、飲料水等を挙げることができる。   Specific examples of the food according to the present invention include tablets, granules, powders, drinks and the like containing the food material according to the present invention as so-called nutritional supplements (supplements). In addition, the seasoning containing the said foodstuff material, confectionery, bread | pan, side dish, drinking water etc. can be mentioned.

本発明に係る食品素材および食品、並びに医薬品はヒトを対象とするものであることはいうまでもないが、ヒトに限定されるものではなく、広く動物全般を対象とすることができる。特に、不適切な食生活や運動不足に陥っているイヌやネコ等の愛玩動物は対象として好適である。   Needless to say, the food materials, foods, and pharmaceuticals according to the present invention are intended for humans, but are not limited to humans and can be used for a wide range of animals. In particular, pets such as dogs and cats who are suffering from inappropriate eating habits and lack of exercise are suitable as targets.

また、本発明は、本発明に係るペプチド混合物を含み、肥満、高脂血症、高血圧症または糖尿病の少なくともいずれかを予防および改善する作用を有する医薬品にも関する。当該ペプチド混合物以外に含まれる成分としては、特に限定されるものではない。本発明の医薬品は経口的に投与できる剤形であることが好ましい。具体的には、例えば、錠剤、顆粒剤、散剤、ドリンク剤、シロップ剤等を挙げることができる。   The present invention also relates to a pharmaceutical comprising the peptide mixture according to the present invention and having an action of preventing and ameliorating at least one of obesity, hyperlipidemia, hypertension and diabetes. The component contained other than the peptide mixture is not particularly limited. The pharmaceutical of the present invention is preferably in a dosage form that can be administered orally. Specific examples include tablets, granules, powders, drinks, and syrups.

以下本発明を実施例によりさらに詳細に説明するが、本発明はこれらの実施例によって限定されるものではない。   EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, this invention is not limited by these Examples.

実施例1(非加熱長いも粉末の製造)
長いもを洗浄し、皮をむき、さらに、3cm幅にカットし、擂りおろし器を用いて擂りおろし、−40℃で冷凍し、凍結乾燥した。凍結乾燥後、粉砕器により粉末にし、試料を調製した。
Example 1 (Production of non-heated long powder)
The long piece was washed, peeled, further cut to a width of 3 cm, ground using a grinder, frozen at −40 ° C., and lyophilized. After lyophilization, the sample was prepared by pulverizing with a pulverizer.

実施例2(ラットへの影響)
使用動物:4週齢のSprague-Dawley (SD)系雄ラットを1群当たり6匹用いた。
順化及び投与:10日間の予備飼育後、21日間、毎日長イモ粉末を餌に混ぜ経口投与した。
餌組成:ラット用飼料配合表対照飼料93を対照群の餌とした。

Figure 2007295833
Example 2 (Influence on rats)
Animals used: Six Sprague-Dawley (SD) male rats aged 4 weeks were used per group.
Acclimatization and administration: After 10 days of preliminary breeding, daily long potato powder was mixed with food and administered orally for 21 days.
Feed composition: Rat feed composition table Control feed 93 was used as a feed for the control group.
Figure 2007295833

投与群では、α化コーンスターチの代わりに非加熱長イモ粉末をそれぞれ15%、30%に置き換えた。さらに、加熱長イモ粉末(1分間熱湯でボイル)についてもそれぞれ15%、30%に置き換えた群を設けた。群分けは体重および血漿コレステロール濃度に有意な差が無いようにコントロール食群、15%非加熱長イモ食群、30%非加熱長イモ食群、15%加熱長イモ食群、30%加熱長イモ食群の6群を設けた。ラットは、個別に飼育し、飼育条件は、室温23±1℃、湿度60±5%、明暗周期が12時間であった。   In the administration group, non-heated long potato powder was replaced with 15% and 30%, respectively, instead of pregelatinized corn starch. Further, a group was also provided in which heated long potato powder (boiled with hot water for 1 minute) was replaced with 15% and 30%, respectively. The grouping is so that there is no significant difference in body weight and plasma cholesterol concentration, control food group, 15% non-heated long potato food group, 30% non-heated long potato food group, 15% heated long potato food group, 30% heated length Six groups of potato food groups were provided. Rats were individually housed under the following conditions: room temperature 23 ± 1 ° C., humidity 60 ± 5%, and light / dark cycle 12 hours.

測定項目:毎週尾静脈より採血し、血漿総コレステロール、HDL−コレステロール、LDL−コレステロール、VLDL−コレステロール、中性脂肪、遊離脂肪酸、およびリン脂質濃度を測定した。血漿総コレステロール、HDL−コレステロール、LDL−コレステロールおよびVLDL−コレステロールは酵素法(コレステロールオキシダーゼ・DAOD法)で、中性脂肪は酵素法(クリニメイトTG−2試薬キット、第一化学薬品)で、遊離脂肪酸はACS(アシル−CoAシンセターゼ)・ACOD(アシルCoAオキシダーゼ)法で、リン脂質は脂質抽出後、クリニメイトIP試薬キット(第一化学薬品)を用いたフィスケ・サロバー法により測定した。さらに、投与最終日3日間の糞便を採取し、その重量を測定した。また、解剖後、肝臓、副睾丸脂肪、睾丸、盲腸を摘出し、その重量を測定した。   Measurement items: Blood was collected from the tail vein every week, and plasma total cholesterol, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol, neutral fat, free fatty acid, and phospholipid concentrations were measured. Plasma total cholesterol, HDL-cholesterol, LDL-cholesterol and VLDL-cholesterol are enzymatic methods (cholesterol oxidase / DAOD method), and neutral fats are enzymatic methods (clinimate TG-2 reagent kit, Daiichi Kagaku). Was measured by the ACS (acyl-CoA synthetase) / ACOD (acyl CoA oxidase) method, and the phospholipid was measured by the Fiske-Sarovar method using a Climate IP reagent kit (Daiichi Kagaku) after lipid extraction. Further, feces were collected for 3 days on the last day of administration and their weights were measured. After dissection, the liver, accessory testicular fat, testicles, and cecum were removed and their weights were measured.

短鎖脂肪酸分析:摘出した盲腸から盲腸内容物をピンセットを用いてコニカルチューブに搾り出し、盲腸内容物の重量を測定した。その後、盲腸内容物を攪拌しながらpHを測定した。次に、盲腸内容物を滅菌超純水で5mlにメスアップし、混合した後、混合液1.5mlを1.5ml遠心チューブに移し、4℃、10,000rpmで10分間遠心分離した。この上澄みの1mlを他の遠心チューブに移し、冷70% HClO 50μlを加えて混合した後、4℃、10,000rpm、10分間遠心分離し、タンパク質を沈殿させた。さらに、この上澄み500μlを別のチューブに移し、4N NaOH 100μlを加えて混合し、4℃、10,000rpmで10分間遠心分離した。上澄み100μlを別のチューブに移し、3N HPO 100μlを加えて混合した。この2μlをガスクロマトグラフィーに供して,短鎖脂肪酸を定量した。 Short chain fatty acid analysis: The cecal contents were extracted from the excised cecum into a conical tube using tweezers, and the weight of the cecal contents was measured. Thereafter, the pH was measured while stirring the contents of the cecum. Next, the contents of the cecum were made up to 5 ml with sterile ultrapure water and mixed, and then 1.5 ml of the mixed solution was transferred to a 1.5 ml centrifuge tube and centrifuged at 10,000 rpm for 10 minutes. 1 ml of this supernatant was transferred to another centrifuge tube, mixed with 50 μl of cold 70% HClO 4 and then centrifuged at 4 ° C., 10,000 rpm for 10 minutes to precipitate the protein. Furthermore, 500 μl of this supernatant was transferred to another tube, mixed with 100 μl of 4N NaOH, and centrifuged at 4 ° C. and 10,000 rpm for 10 minutes. 100 μl of the supernatant was transferred to another tube, and 100 μl of 3N H 3 PO 4 was added and mixed. 2 μl of this was subjected to gas chromatography to quantify short chain fatty acids.

結果
解剖時の腹部大動脈血の血漿脂質濃度を表1に示した。尾静脈血漿のコレステロール変動とは異なり、総コレステロール濃度に有意な差は認められなかった。しかしながら、30RY群の血漿コレステロール濃度は低下傾向であった。VLDL−コレステロール濃度はコントロール食群に比べ、30RY群で有意に低下した。動脈硬化指数(AI:Atherogenic index)はコントロール食群に比べ、有意に30RY群で有意に低かった。トリグリセリド濃度はコントロール食群に比べ、15RY群、30RY群、30BY群有意に低下し、RY群間では用量依存的に低下が認められた。リン脂質濃度はコントロール食群に比べ、30RY群のみ有意に低下した。
Results Table 1 shows plasma lipid concentrations of abdominal aortic blood at the time of dissection. Unlike cholesterol variation in tail vein plasma, no significant difference was observed in total cholesterol concentration. However, the plasma cholesterol concentration in the 30RY group tended to decrease. The VLDL-cholesterol concentration was significantly reduced in the 30RY group compared to the control food group. The arteriosclerosis index (AI) was significantly lower in the 30RY group than in the control diet group. The triglyceride concentration was significantly decreased in the 15RY group, the 30RY group, and the 30BY group as compared to the control food group, and a decrease was observed between the RY groups in a dose-dependent manner. The phospholipid concentration was significantly reduced only in the 30RY group compared to the control diet group.

Figure 2007295833
Figure 2007295833

30RY群の血漿脂質濃度低下はいずれの脂質濃度にも認められ、生の長いもが、いくつかの機構により脂質代謝を調節する可能性が示唆された。   A decrease in plasma lipid concentration in the 30RY group was observed at any lipid concentration, suggesting the possibility that long-lived may regulate lipid metabolism by several mechanisms.

表2には、盲腸内容物中の短鎖脂肪酸およびコハク酸の量および濃度を示した。生の長いも(RY)を与えたラットの盲腸は肥大したため、盲腸内容物中の短鎖脂肪酸量はRY摂取により有意にいずれも増加した。その増加は容量依存的であった。コハク酸量はばらつきがあるものの、コントロール食群に比べ30RY群で有意に増加した。ボイル長いも(BY)の投与ラットの短鎖脂肪酸量も一部増加傾向は認められたが、RY投与ラットに比べ有意に低かった。   Table 2 shows the amount and concentration of short chain fatty acids and succinic acid in the cecal contents. Since the cecum of rats fed with raw long potato (RY) was enlarged, the amount of short-chain fatty acids in the cecal contents was significantly increased by RY intake. The increase was volume dependent. Although the amount of succinic acid varied, it significantly increased in the 30RY group compared to the control food group. Although some of the short-chain fatty acids in the boiled buttery (BY) -treated rats were also partially increased, they were significantly lower than those in the RY-treated rats.

Figure 2007295833
Figure 2007295833

一方、短鎖脂肪酸である酢酸およびプロピオン酸濃度は、30RY群のプロピオン酸を除き、各処理群間で、ほとんど差が認められなかった。酪酸濃度は、加熱処理の有無にかかわらず長いもを与えたラットで有意に2〜2.5倍の増加が認められた。このため、盲腸内容物中の短鎖脂肪酸比率はコントロール食群で酢酸主体であったものが、長いも摂取により酢酸と(プロピオン酸+酪酸)の比率が5:5となり、大腸内発酵の変動が確認された。この変動は、酪酸発酵が盛んになったためと推察される。酪酸は大腸上皮細胞の増殖に欠かせないことや大腸ガン抑制作用があることが知られている。   On the other hand, the concentrations of acetic acid and propionic acid, which are short-chain fatty acids, were hardly different among the treatment groups except for 30RY group propionic acid. The butyric acid concentration was significantly increased 2- to 2.5-fold in rats given a long time regardless of the presence or absence of heat treatment. For this reason, the ratio of short-chain fatty acids in the cecum contents was mainly acetic acid in the control diet group, but the ratio of acetic acid to (propionic acid + butyric acid) became 5: 5 by ingestion for a long time. confirmed. This change is presumed to be due to the increase in butyric acid fermentation. It is known that butyric acid is indispensable for the growth of colonic epithelial cells and has a colon cancer inhibitory effect.

すなわち、これらの実験により、下記の効果が認められた。
30%非加熱長いも食群において、血漿コレステロール濃度が有意に低下した。
盲腸内容物、盲腸壁重量及び短鎖脂肪酸濃度は非加熱長いもの摂取により有意に増加した(図2)。一方、盲腸内容物pHは非加熱長いもの摂取量に依存して低下し(図3)、長いもの摂取によって発酵が促進された。
糞中胆汁酸排泄量はコントロール食群に比べ、加熱長イモを摂取した両群で有意に増加し、非加熱長イモを摂取した両群では変化は認められなかった。このため、30%非加熱長イモ群で認められた血漿コレステロール濃度の低下は、胆汁酸排泄の増加が関与しているのではなく、肝臓へのコレステロールの取り込みもしくは肝臓コレステロール合成の変動が寄与していると推察される。
That is, the following effects were recognized by these experiments.
Plasma cholesterol levels were significantly reduced in the 30% non-heated long diet group.
The cecal contents, cecal wall weight, and short chain fatty acid concentration increased significantly with ingestion of non-heated long substances (FIG. 2). On the other hand, the pH of the cecum content decreased depending on the intake amount of the non-heated long substance (FIG. 3), and fermentation was promoted by the long intake.
Fecal bile acid excretion was significantly increased in both groups ingested heated long potato compared to the control diet group, and no change was observed in both groups ingested unheated long potato. For this reason, the decrease in plasma cholesterol concentration observed in the 30% unheated long potato group is not due to increased bile acid excretion, but is due to fluctuations in cholesterol uptake into the liver or liver cholesterol synthesis. It is inferred that

本発明の食品は、不適切な食生活又は運動不足に起因する生活習慣病を予防又は改善のために有用である。   The food of the present invention is useful for preventing or ameliorating lifestyle-related diseases caused by inappropriate eating habits or lack of exercise.

血漿コレステロール濃度変動Plasma cholesterol concentration fluctuation 盲腸内容物および盲腸壁重量Cecal contents and cecal wall weight 盲腸内容物pH、糞中総胆汁酸量Cecal content pH, fecal total bile acid content

Claims (1)

非加熱長いも粉末を含む、生活習慣病の予防食品又は生活習慣病の改善食品。   A food for preventing lifestyle-related diseases or a food for improving lifestyle-related diseases, comprising non-heated long powder.
JP2006125678A 2006-04-28 2006-04-28 Life style disease-preventive food containing frozen dry powder of dioscorea batatas Pending JP2007295833A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006125678A JP2007295833A (en) 2006-04-28 2006-04-28 Life style disease-preventive food containing frozen dry powder of dioscorea batatas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006125678A JP2007295833A (en) 2006-04-28 2006-04-28 Life style disease-preventive food containing frozen dry powder of dioscorea batatas

Publications (1)

Publication Number Publication Date
JP2007295833A true JP2007295833A (en) 2007-11-15

Family

ID=38765883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006125678A Pending JP2007295833A (en) 2006-04-28 2006-04-28 Life style disease-preventive food containing frozen dry powder of dioscorea batatas

Country Status (1)

Country Link
JP (1) JP2007295833A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000279141A (en) * 1999-03-30 2000-10-10 Akasaki Tetsuro Molokheiya tea and food composition containing molokheiya
JP2002275075A (en) * 2001-03-15 2002-09-25 Fancl Corp Crude drug powder-containing solid composition and method for producing the same
JP2002281938A (en) * 2001-03-27 2002-10-02 Global Core:Kk Food for improving physical constitution
WO2005082391A1 (en) * 2004-03-01 2005-09-09 Kaneka Corporation AGONIST TO HUMAN β3 ADRENALINE RECEPTOR
JP2006025662A (en) * 2004-07-14 2006-02-02 Nippon Pack Kk Health food

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000279141A (en) * 1999-03-30 2000-10-10 Akasaki Tetsuro Molokheiya tea and food composition containing molokheiya
JP2002275075A (en) * 2001-03-15 2002-09-25 Fancl Corp Crude drug powder-containing solid composition and method for producing the same
JP2002281938A (en) * 2001-03-27 2002-10-02 Global Core:Kk Food for improving physical constitution
WO2005082391A1 (en) * 2004-03-01 2005-09-09 Kaneka Corporation AGONIST TO HUMAN β3 ADRENALINE RECEPTOR
JP2006025662A (en) * 2004-07-14 2006-02-02 Nippon Pack Kk Health food

Similar Documents

Publication Publication Date Title
Kim et al. Effect of resistant starch from corn or rice on glucose control, colonic events, and blood lipid concentrations in streptozotocin-induced diabetic rats
Ramírez-Jiménez et al. Potential role of bioactive compounds of Phaseolus vulgaris L. on lipid-lowering mechanisms
de Deckere et al. Both raw and retrograded starch decrease serum triacylglycerol concentration and fat accretion in the rat
AU2007203186B2 (en) The healthy and functional foods for the obesity patients using purple-colored potato
CN101755872B (en) Cake component for diabetic patients
JP2013010762A (en) Starch subtype and lipid metabolism
CN1662258A (en) Compositions comprising dietary fat complexer and methods for their use
Halaby et al. Potential effect of date pits fortified bread on diabetic rats
CA2573261A1 (en) Compositions for enhancing the production of ppar and/or ppar-associated factors
Nishimura et al. Raw Chinese yam (Dioscorea opposita) promotes cecal fermentation and reduces plasma non-HDL cholesterol concentration in rats
CN114128890A (en) Nutritional supplement composition
Dakia Carob (Ceratonia siliqua L.) seeds, endosperm and germ composition, and application to health
CN101766281A (en) Resistant starch rice noodles with good taste
CN108713755A (en) Quinoa weight reducing nutrition milk shake
JP2007295833A (en) Life style disease-preventive food containing frozen dry powder of dioscorea batatas
CN107712875A (en) Black quinoa weight losing meal-replacing
Malang Effect of consumption of Coleus tuberosus on the lipid profile of alloxan-induced diabetic rats
JP2011200221A (en) Method for manufacturing special starch food for applying to metabolic syndrome, and product manufactured by the same
JP2011173813A (en) PPARalpha EXPRESSION PROMOTER
JP2007001925A (en) Lipid metabolism ameliorator, and food/drink and feed each containing the same
Tugbobo et al. Dietary protection by Tapinanthus globiferus (Mistletoe) leaf extract against prontosil-induced clastogenicity in mice in vivo
Carboni et al. Impact of lentil-wheat bread on calcium metabolism, cecal and serum parameters in growing Wistar rats
Melaku Investigating the effects of teff-sorghum-fenugreek flour blending ratios on quality attributes of injera
JP2012188426A (en) Lipid metabolism-improving composition
Pella et al. Do modern eggs, but not wild-type eggs, increase the risk of cardiovascular disease, diabetes, and cancer?

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090416

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090529

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090529

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090529

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110301